Basic Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. May 28, 2023; 29(20): 3103-3118
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3103
Table 1 The drugs with the highest affinity of transforming growth factor β type II receptor
Name
ZINC_ID
Affinity (kcal/mol)
Indications
DarifenacinZINC000001996117-7.6Urinary frequency, urgency, and incontinence caused by bladder hyperstimulation
CyproheptadineZINC000000968264-7.4Allergy
LifitegrastZINC000084668739-7.4Symptoms and signs of dry eye
DifenoxinZINC000000601317-7.3Functional diarrhea and chronic enteritis
PhenytoinZINC000002510358-7.3Epilepsy, neuralgia, and arrhythmia
DHEZINC000003978005-7.3Severe orthostatic hypotension, migraine, and headache
NaldemedineZINC000100378061-7.3Non-cancerous pain and opioid induced constipation
IrinotecanZINC000001612996-7.3Advanced colorectal cancer and postoperative adjuvant chemotherapy
Table 2 Content of secondary structural analysis from DSSP method
Structure
Coil
β-Sheet
β-Bridge
Bend
Turn
3-Helix
TGFβR20.580.30.420.020.120.13
TGFβR2-DHE0.560.30.420.020.120.12
Table 3 DNA sequence of extracellular transforming growth factor β type II receptor before and after mutation

Before mutation
After mutation
DNA sequence of TGFβR2 extracellular domainACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAACTGTGTAAATTTTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCACCTCCATCTGTGAGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAAACGATCCCACCGCACGTTCAGAAGTCGGTTAATAACGACATGATAGTCACTGACAACAACGGTGCAGTCAAGTTTCCACAAGCGTGTAAAGCGTGTGATGTGAGATTTTCCACCTGTGACAACCAGAAATCCTGCATGAGCAACTGCAGCATCGCGGCGGCGTGTGCGAAGCCACAGGAAGTCTGTGTGGCTGTATGGAGAAAGAATGACGAGAACATAACACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTACCATGACTTTATTCTGGAAGATGCTGCTTCTCCAAAGTGCATTATGAAGGAAAAAAAAAAGCCTGGTGAGACTTTCTTCATGTGTTCCTGTAGCTCTGATGAGTGCAATGACAACATCATCTTCTCAGAAGAATATAACACCAGCAATCCTGACTTGTTGCTAGTCATATTTCAA